In summary, our study shows that KRASG12C inhibitors induce the formation of primary cilia and activate Hh signaling, which is responsible for re-expression of KRAS and reacquired resistance against KRASG12C inhibitors in cancer cells. The gene discussed is KRAS; the disease is cancer.